Clinical Management in BRCA Carriers with Early Breast Cancer

Area of Science:

• Oncology
• Genetics
• Medical Imaging

Background:

• Breast cancer in BRCA1/2 mutation carriers presents unique challenges, including aggressive tumor biology and increased risks.
• Latin America shows variable BRCA prevalence, necessitating region-specific genetic screening strategies.

Purpose of the Study:

• To review and synthesize current evidence on managing early-stage breast cancer in BRCA mutation carriers.
• To highlight the need for region-specific genetic screening and tailored management approaches.

Main Methods:

• Systematic review of evidence on therapeutic strategies, imaging, and surgical management.
• Analysis of clinical trial data (e.g., OlympiA, KEYNOTE-522) and observational studies.
• Consideration of specific populations, including transgender individuals.

Main Results:

• PARP inhibitors like Olaparib demonstrate survival benefits in BRCA carriers.
• MRI is favored for imaging due to mammography-elusive tumors in BRCA1 carriers; abbreviated protocols offer efficiency.
• Risk-adapted surgery (mastectomy vs. breast-conserving surgery) requires careful consideration of contralateral cancer risk.
• Neoadjuvant platinum chemotherapy shows promise, particularly for triple-negative subtypes.

Conclusions:

• Optimizing care for BRCA carriers necessitates multidisciplinary, personalized strategies integrating genetic, regional, and clinical factors.
• Shared decision-making and ongoing research are vital for addressing survivorship and ensuring equitable care.